Terms: = Bone cancer AND CD79B, ENSG00000007312, 974, P40259, IGB, B29 AND Treatment
31 results:
1. Development and Validation of a Convolutional Neural Network Model to Predict a Pathologic Fracture in the Proximal Femur Using Abdomen and Pelvis CT Images of Patients With Advanced cancer.
Joo MW; Ko T; Kim MS; Lee YS; Shin SH; Chung YG; Lee HK
Clin Orthop Relat Res; 2023 Nov; 481(11):2247-2256. PubMed ID: 37615504
[TBL] [Abstract] [Full Text] [Related]
2. New insights into breast microcalcification for poor prognosis: NACT cohort and bone metastasis evaluation cohort.
Hu Y; Mao L; Wang M; Li Z; Li M; Wang C; Ji L; Zeng H; Zhang X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7285-7297. PubMed ID: 36917189
[TBL] [Abstract] [Full Text] [Related]
3. Preoperative Prediction of Sinonasal Inverted Papilloma-associated Squamous Cell Carcinoma (IP-SCC).
Park MJ; Cho W; Kim JH; Chung YS; Jang YJ; Yu MS
Laryngoscope; 2023 Oct; 133(10):2502-2510. PubMed ID: 36683553
[TBL] [Abstract] [Full Text] [Related]
4. Machine learning predicts the prognosis of breast cancer patients with initial bone metastases.
Li C; Liu M; Li J; Wang W; Feng C; Cai Y; Wu F; Zhao X; Du C; Zhang Y; Wang Y; Zhang S; Qu J
Front Public Health; 2022; 10():1003976. PubMed ID: 36225783
[TBL] [Abstract] [Full Text] [Related]
5. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Gouni S; Rosenthal AC; Crombie JL; Ip A; Kamdar MK; Hess B; Feng L; Watson G; Ayers A; Neelapu SS; Khurana A; Lin Y; Iqbal M; Merryman RW; Strati P
Blood Adv; 2022 May; 6(9):2757-2762. PubMed ID: 35240681
[TBL] [Abstract] [Full Text] [Related]
6. EIF3B Associates with Exacerbated Clinical Features, Poor treatment Response and Survival in Adult Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Patients.
Zhu F; Fu Y; He X
Technol Cancer Res Treat; 2021; 20():15330338211041464. PubMed ID: 34617851
[No Abstract] [Full Text] [Related]
7. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract] [Full Text] [Related]
8. Radiation exposure during the treatment of spinal deformities.
Mehta JS; Hodgson K; Yiping L; Kho JSB; Thimmaiah R; Topiwala U; Sawlani V; Botchu R
Bone Joint J; 2021 Apr; 103-B(4):1-7. PubMed ID: 33595351
[TBL] [Abstract] [Full Text] [Related]
9. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
[TBL] [Abstract] [Full Text] [Related]
10. Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease.
Ruben CL; Pirsl F; Steinberg SM; Holtzman NG; Parsons-Wandell L; Baruffaldi J; Curtis LM; Mitchell SA; Kerep AZ; Cowen EW; Berger A; Joe GO; Datiles MB; Mays JW; Pavletic SZ
Bone Marrow Transplant; 2021 Jul; 56(7):1584-1592. PubMed ID: 33526918
[TBL] [Abstract] [Full Text] [Related]
11. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
[TBL] [Abstract] [Full Text] [Related]
12. On point in primary CNS lymphoma.
Tsang M; Cleveland J; Rubenstein JL
Hematol Oncol; 2020 Dec; 38(5):640-647. PubMed ID: 32510610
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line treatment of Tyrosine Kinase Inhibitors.
Li XY; Zhu XR; Zhang CC; Yu W; Zhang B; Shen TL; Zhang HY; Fu XL
Clin Lung Cancer; 2020 Nov; 21(6):534-544. PubMed ID: 32505632
[TBL] [Abstract] [Full Text] [Related]
14. Patterns of metastases of prostatic ductal adenocarcinoma.
Ranasinghe WKB; Brooks NA; Elsheshtawi MA; Davis JW; Bathala TK; Tang C; Troncoso P; Aparicio A; Tu SM; Pisters LL; Chapin BF
Cancer; 2020 Aug; 126(16):3667-3673. PubMed ID: 32453443
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract] [Full Text] [Related]
16. Fracture types affect clinical outcomes of patients managed within the fracture liaison and osteoporosis medication management services.
Chang CB; Yang RS; Chang LY; Peng JK; Tsai KS; Huang WJ; Yang TH; Chan DC
Sci Rep; 2019 Jul; 9(1):10089. PubMed ID: 31300660
[TBL] [Abstract] [Full Text] [Related]
17. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.
Autore F; Strati P; Laurenti L; Ferrajoli A
Haematologica; 2018 Jun; 103(6):931-938. PubMed ID: 29748447
[TBL] [Abstract] [Full Text] [Related]
18. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
[TBL] [Abstract] [Full Text] [Related]
19. Genomics, Signaling, and treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract] [Full Text] [Related]
20. Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
Adnan Awad S; Kamel MM; Ayoub MA; Kamel AM; Elnoshokaty EH; El Hifnawi N
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S19-S24.e1. PubMed ID: 27521317
[TBL] [Abstract] [Full Text] [Related]
[Next]
